Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  American Journal of Respiratory and Critical Care Medicine

• Publication date

  2012-12-14

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1164/rccm.201106-1093OCPMID 22161164
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Vascular microRNAs.

  2010cited by this paper
• Basic Science of Pulmonary Arterial Hypertension for Clinicians: New Concepts and Experimental Therapies

  2010cited by this paper
• Dynamic Changes in Lung MicroRNA Profiles During the Development of Pulmonary Hypertension due to Chronic Hypoxia and Monocrotaline

  2010influential reference
• MicroRNA‐21 plays a Role in Hypoxia‐mediated Pulmonary Artery Smooth Muscle Cell Proliferation and Migration

  2010influential reference
• Integrative Physiology/Experimental Medicine MicroRNAs Are Necessary for Vascular Smooth Muscle Growth, Differentiation, and Function

  2010cited by this paper
• Proteomic Analysis of Lung Tissues From Patients With Pulmonary Arterial Hypertension

  2010cited by this paper
• Members of the microRNA-17-92 cluster exhibit a cell-intrinsic antiangiogenic function in endothelial cells.

  2010cited by this paper
• Interleukin-6 Modulates the Expression of the Bone Morphogenic Protein Receptor Type II Through a Novel STAT3–microRNA Cluster 17/92 Pathway

  2009influential reference
• MicroRNA-92a Controls Angiogenesis and Functional Recovery of Ischemic Tissues in Mice

  2009cited by this paper
• Altered Bone Morphogenetic Protein and Transforming Growth Factor-β Signaling in Rat Models of Pulmonary Hypertension: Potential for Activin Receptor-Like Kinase-5 Inhibition in Prevention and Progression of Disease

  2009cited by this paper
• Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure.

  2009cited by this paper
• miR-17 and miR-20a temper an E2F1-induced G1 checkpoint to regulate cell cycle progression

  2009cited by this paper
• Molecular pathogenesis of pulmonary arterial hypertension.

  2008cited by this paper
• Antagomir-17-5p Abolishes the Growth of Therapy-Resistant Neuroblastoma through p21 and BIM

  2008cited by this paper
• MicroRNA-17-92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes.

  2008cited by this paper
• Inflammation, endothelial injury, and persistent pulmonary hypertension in heterozygous BMPR2-mutant mice.

  2008cited by this paper
• miR-126 regulates angiogenic signaling and vascular integrity.

  2008cited by this paper
• Antagomir-mediated silencing of endothelial cell specific microRNA-126 impairs ischemia-induced angiogenesis

  2008cited by this paper
• Emerging role of miR-106b-25/miR-17-92 clusters in the control of transforming growth factor beta signaling.

  2008cited by this paper
• Identification of hypoxia-inducible factor-1 alpha as a novel target for miR-17-92 microRNA cluster.

  2008cited by this paper
• Molecular pathogenesis of pulmonary arterial hypertension.

  2008cited by this paper
• Synergistic action of the microRNA‐17 polycistron and Myc in aggressive cancer development

  2007cited by this paper
• MicroRNA Expression Signature and Antisense-Mediated Depletion Reveal an Essential Role of MicroRNA in Vascular Neointimal Lesion Formation

  2007cited by this paper
• Dysregulated Bone Morphogenetic Protein Signaling in Monocrotaline-Induced Pulmonary Arterial Hypertension

  2007cited by this paper
• MicroRNAs in the Human Heart: A Clue to Fetal Gene Reprogramming in Heart Failure

  2007cited by this paper
• A microRNA expression signature of human solid tumors defines cancer gene targets

  2006cited by this paper
• Silencing of microRNAs in vivo with ‘antagomirs’

  2005cited by this paper
• Prediction of mammalian microRNA targets.

  2003cited by this paper
• Expression of genes involved in vascular development and angiogenesis in endothelial cells of adult lung.

  2003influential reference
• Stimulation of Id1 Expression by Bone Morphogenetic Protein Is Sufficient and Necessary for Bone Morphogenetic Protein–Induced Activation of Endothelial Cells

  2002influential reference
• Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty.

  1995cited by this paper

• Challenges and opportunities in targeting epigenetic mechanisms for pulmonary arterial hypertension treatment.

  2025cites this paper
• Decreased endothelial micro-RNA-30b-5p impairs angiogenesis in fetal lambs with persistent pulmonary hypertension

  2025cites this paper
• Multiomics Integration for Identifying Treatment Targets, Drug Development, and Diagnostic Designs in PAH

  2025cites this paper
• Key Amniotic Fluid miRNAs as Promising Target Molecules for the Antenatal Prevention of Pulmonary Hypoplasia Associated with Congenital Diaphragmatic Hernia

  2025cites this paper
• The Pleiotropic Role of the MicroRNA-17-92 Cluster in Cardiovascular Diseases and Cancer

  2025cites this paper
• Editorial: Exploring the role of epigenetic modifications in pulmonary vascular disease pathogenesis

  2025cites this paper
• CircRNA-based AntimiR therapy: A novel approach to hypertension treatment

  2025cites this paper
• Maternal Plasma Micro-RNAs in Fetal Congenital Diaphragmatic Hernia: A Potential Non-Invasive Tool for Prenatal Diagnosis and Risk Stratification.

  2025cites this paper
• Signaling pathways and targeted therapy for pulmonary hypertension

  2025cites this paper
• LncRNA-536 and RNA-Binding Protein RBM25 Interactions in Pulmonary Artery Smooth Muscle Cells: Implications in Pulmonary Hypertension.

  2025cites this paper
• Pathophysiology of Group 3 Pulmonary Hypertension Associated with Lung Diseases and/or Hypoxia

  2025cites this paper
• The pharmaco-epigenetics of hypertension: a focus on microRNA

  2024cites this paper
• N6-methyladenosine modification of KLF2 may contribute to endothelial-to-mesenchymal transition in pulmonary hypertension

  2024cites this paper
• LncRNA-536 and RNA Binding Protein RBM25 Interactions in Pulmonary Arterial Hypertension

  2024cites this paper
• miR‐30d Attenuates Pulmonary Arterial Hypertension via Targeting MTDH and PDE5A and Modulates the Beneficial Effect of Sildenafil

  2024cites this paper
• Targeting Soluble TGF-β Factors

  2024cites this paper
• Unraveling the epigenetic landscape of pulmonary arterial hypertension: implications for personalized medicine development

  2023cites this paper
• Pulmonary vascular fibrosis in pulmonary hypertension - The role of the extracellular matrix as a therapeutic target.

  2023cites this paper
• Inhibition of miR-195-3p protects against cardiac dysfunction and fibrosis after myocardial infarction.

  2023cites this paper
• MicroRNAs and their regulators: Potential therapeutic targets in pulmonary arterial hypertension.

  2023cites this paper
• Molecular Insight into the Therapeutic Effects of Stem Cell-Derived Exosomes in Respiratory Diseases and the Potential for Pulmonary Delivery

  2022cites this paper
• Group 3 Pulmonary Hypertension: From Bench to Bedside

  2022cites this paper
• Nebulization of extracellular vesicles: A promising small RNA delivery approach for lung diseases.

  2022cites this paper
• Yiqi Fumai lyophilized injection ameliorates pulmonary arterial hypertension induced right heart dysfunction through ACE2-Ang (1-7)-Mas axis and PI3K/Akt/eNOS pathway

  2022cites this paper
• Maternal and perinatal obesity induce bronchial obstruction and pulmonary hypertension via IL-6-FoxO1-axis in later life

  2022cites this paper
• Fetal pulmonary hypertension: dysregulated microRNA-34c-Notch1 axis contributes to impaired angiogenesis in an ovine model

  2022cites this paper
• Inhibition of miR-21 improves pulmonary vascular responses in bronchopulmonary dysplasia by targeting the DDAH1/ADMA/NO pathway

  2022cites this paper
• MircoRNA in Extracellular Vesicles from Patients with Pulmonary Arterial Hypertension Alters Endothelial Angiogenic Response

  2022cites this paper
• MicroRNAs in Pulmonary Hypertension, from Pathogenesis to Diagnosis and Treatment

  2022cites this paper
• Differential expression of aqueous humor microRNAs in central retinal vein occlusion and its association with matrix metalloproteinases: a pilot study

  2022cites this paper
• Biomarker-based approach to determine etiology and severity of pulmonary hypertension: Focus on microRNA

  2022cites this paper
• Circulating Microparticles Are Differentially Increased in Lowlanders and Highlanders with High Altitude Induced Pulmonary Hypertension during the Cold Season

  2022cites this paper
• Molecular Pathways in Pulmonary Arterial Hypertension

  2022cites this paper
• Experimental Models

  2021cites this paper
• Targeting Molecular and Cellular Mechanisms of Pulmonary Arterial Hypertension

  2021cites this paper
• Novel Pharmacological Targets for Pulmonary Arterial Hypertension.

  2021cites this paper
• PPARγ increases HUWE1 to attenuate NF-κB/p65 and sickle cell disease with pulmonary hypertension.

  2021cites this paper
• MicroRNAs and Heat Shock Proteins in Breast Cancer Biology.

  2021cites this paper
• Mitochondria in the Pulmonary Vasculature in Health and Disease: Oxygen-Sensing, Metabolism, and Dynamics.

  2020cites this paper
• MiRNAs, lncRNAs, and circular RNAs as mediators in hypertension-related vascular smooth muscle cell dysfunction

  2020cites this paper
• MicroRNA-17 as a potential diagnostic biomarker in pulmonary arterial hypertension

  2020cites this paper
• The roles of endothelin and its receptors in cigarette smoke-associated pulmonary hypertension with chronic lung disease.

  2020cites this paper
• Epigenetic targets for oligonucleotide therapies of pulmonary hypertension

  2020cites this paper
• MicroRNA Nanotherapeutics for Lung Targeting. Insights into Pulmonary Hypertension

  2020cites this paper
• Targeting respiratory diseases using miRNA inhibitor based nanotherapeutics: Current status and future perspectives.

  2020cites this paper
• hsa-miR-106b-5p participates in the development of chronic thromboembolic pulmonary hypertension via targeting matrix metalloproteinase 2

  2020cites this paper
• CAR (CARSKNKDC) Peptide Modified ReNcell-Derived Extracellular Vesicles as a Novel Therapeutic Agent for Targeted Pulmonary Hypertension Therapy

  2020cites this paper
• The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension.

  2020cites this paper
• Epigenetic Targets for Oligonucleotide Therapies of Pulmonary Arterial Hypertension

  2020cites this paper
• An omic approach to congenital diaphragmatic hernia: a pilot study of genomic, microRNA, and metabolomic profiling

  2020cites this paper
• Novel Advances in Modifying BMPR2 Signaling in PAH

  2020cites this paper
• Micro-RNA Analysis in Pulmonary Arterial Hypertension

  2020cites this paper
• Genomic analysis of circular RNAs in heart

  2020cites this paper
• Exosomal miR-211 contributes to pulmonary hypertension via attenuating CaMK1/PPAR-γaxis.

  2020cites this paper
• ‘There and Back Again’—Forward Genetics and Reverse Phenotyping in Pulmonary Arterial Hypertension

  2020cites this paper
• Genetic deletion of p66shc and/or cyclophilin D results in decreased pulmonary vascular tone

  2020cites this paper
• MicroRNAs in Respiratory Diseases

  2019cites this paper
• Angiogenesis in Pulmonary Arterial Hypertension-Imaging of the Right Heart in a New Mouse Model

  2019cites this paper
• Elucidating the contributory role of microRNA to cardiovascular diseases (a review)

  2019cites this paper
• Clinical values of non-coding RNAs in cardiovascular, pulmonary, and muscle diseases.

  2019cites this paper
• Effects of AntagomiRs on Different Lung Diseases in Human, Cellular, and Animal Models

  2019cites this paper
• Joint Transcriptomic Analysis of Lung Cancer and Other Lung Diseases

  2019cites this paper
• Hypoxia Promotes Vascular Smooth Muscle Cell Proliferation through microRNA-Mediated Suppression of Cyclin-Dependent Kinase Inhibitors

  2019cites this paper
• Cardamonin protects against doxorubicin-induced cardiotoxicity in mice by restraining oxidative stress and inflammation associated with Nrf2 signaling.

  2019cites this paper
• Inhibition of miR-495 Improves Both Vascular Remodeling and Angiogenesis in Pulmonary Hypertension

  2019cites this paper
• Targeting cyclin-dependent kinases for the treatment of pulmonary arterial hypertension

  2019cites this paper
• Can microsomal RNA be a biomarker in pulmonary hypertension secondary to bronchopulmonary dysplasia?

  2019cites this paper
• Right heart in pulmonary hypertension: from adaptation to failure

  2019cites this paper
• Noncoding RNAs in Hypertension

  2019cites this paper
• Targeting epigenetic mechanisms as an emerging therapeutic strategy in pulmonary hypertension disease

  2019cites this paper
• Altered proteasome function in right ventricular hypertrophy.

  2019cites this paper
• PAI-1 is a novel component of the miR-17~92 signaling that regulates pulmonary artery smooth muscle cell phenotypes.

  2018cites this paper
• Mitochondrial dysfunction and pulmonary hypertension: cause, effect, or both.

  2018cites this paper
• Title : Mitochondrial dysfunction and pulmonary hypertension : Cause , Effect or Both 1 2

  2018cites this paper
• Upregulation of microRNA-17-5p contributes to hypoxia-induced proliferation in human pulmonary artery smooth muscle cells through modulation of p21 and PTEN

  2018cites this paper
• Epigenetic Regulation and Its Therapeutic Potential in Pulmonary Hypertension

  2018cites this paper
• miR-190a-5p participates in the regulation of hypoxia-induced pulmonary hypertension by targeting KLF15 and can serve as a biomarker of diagnosis and prognosis in chronic obstructive pulmonary disease complicated with pulmonary hypertension

  2018cites this paper
• MicroRNA Dysregulation in Pulmonary Arteries from Chronic Obstructive Pulmonary Disease. Relationships with Vascular Remodeling

  2018cites this paper
• Pulmonary arterial hypertension: pathogenesis and clinical management

  2018cites this paper
• Hypoxia-induced changes in plasma micro-RNAs correlate with pulmonary artery pressure at high altitude.

  2018influential citation
• mir-190a-5p participates in the regulation of hypoxia-induced pulmonary hypertension by targeting KlF15 and can serve as a biomarker of diagnosis and prognosis in chronic obstructive pulmonary disease complicated with pulmonary hypertension

  2018cites this paper
• Anti‐apoptosis endothelial cell‐secreted microRNA‐195‐5p promotes pulmonary arterial smooth muscle cell proliferation and migration in pulmonary arterial hypertension

  2018cites this paper
• p53-mediated miR-18 repression activates HSF2 for IGF-IIR-dependent myocyte hypertrophy in hypertension-induced heart failure

  2017cites this paper
• Pathophysiology of Pulmonary Hypertension

  2017cites this paper
• The influence of sex on the in vivo and in vitro effects of treprostinil in pulmonary arterial hypertension

  2017cites this paper
• Peroxisome Proliferator‐Activated Receptor &ggr; Regulates the V‐Ets Avian Erythroblastosis Virus E26 Oncogene Homolog 1/microRNA‐27a Axis to Reduce Endothelin‐1 and Endothelial Dysfunction in the Sickle Cell Mouse Lung

  2017cites this paper
• Role and Regulation of MicroRNAs in Aldosterone-Mediated Cardiac Injury and Dysfunction in Male Rats

  2017cites this paper
• Translational Advances in the Field of Pulmonary Hypertension. Translating MicroRNA Biology in Pulmonary Hypertension. It Will Take More Than “miR” Words

  2017cites this paper
• Targeting Vascular Remodeling to Treat Pulmonary Arterial Hypertension.

  2017cites this paper
• Novel putative pharmacological therapies to protect the right ventricle in pulmonary hypertension: a review of current literature

  2017influential citation
• Assessment of microRNA and gene dysregulation in pulmonary hypertension by endoarterial biopsy

  2017cites this paper
• MicroRNA-222 Promotes the Proliferation of Pulmonary Arterial Smooth Muscle Cells by Targeting P27 and TIMP3

  2017cites this paper
• MicroRNAs in right ventricular remodelling

  2017cites this paper
• Critical effects of epigenetic regulation in pulmonary arterial hypertension

  2017cites this paper
• Emerging Role of MicroRNAs and Long Noncoding RNAs in Healthy and Diseased Lung.

  2017cites this paper
• Regulation of NKX2-5 in blood vessels

  2017cites this paper
• The cancer theory of pulmonary arterial hypertension

  2017cites this paper
• Discerning functional hierarchies of microRNAs in pulmonary hypertension.

  2017cites this paper
• Pathogenic and Therapeutic Role of MicroRNA in Pulmonary Arterial Hypertension

  2017cites this paper
• Amplified canonical transforming growth factor-β signalling via heat shock protein 90 in pulmonary fibrosis

  2017cites this paper